Tenax Therapeutics, Inc. (TENX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.67K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.67K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | - | - | - | - | - | - |
| Operating Expenses | 16.57M | 16.45M | 16.81M | 11.79M | 11.34M | 7.29M | -4.62M | 3.67M | 3.91M | 3.34M | -2.12M | -1.24M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.03M | 5.91M | 6.48M | 5.67M | 5.66M | 2.7M | 1.51M | 1.34M | 1.23M | 1.64M | 1.05M | 1.04M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 11.54M | 10.54M | 10.33M | 6.12M | 5.68M | 4.59M | 3.11M | 2.33M | 2.68M | 1.7M | 1.07M | 197.9K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -1000K | 0 | 0 | 0 | -1000K | -1000K |
| Operating Income | -16.57M | -16.45M | -16.81M | -11.79M | -11.34M | -7.29M | 4.62M | -3.67M | -3.91M | -3.34M | 2.12M | 1.24M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -46.17% | -125.49% | -463.85% | -221.22% | -190.05% | -118.35% | 118.14% | -396.97% | -153.92% | 82.91% | -27.42% | -56.81% |
| EBITDA | -16.57M | -15.54M | -15.8M | -10.85M | -10.41M | -6.27M | -3.95M | -3.57M | -3.79M | -3.34M | 2.12M | 1.24M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -59.23% | -147.96% | -299.68% | -204.18% | -174.54% | -87.85% | -286.66% | -388.24% | -146.4% | 82.93% | -28.09% | -57.19% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.67K | 969 | 1K |
| EBIT | -16.57M | -15.54M | -15.8M | -10.85M | -10.41M | -6.27M | -3.95M | -3.57M | -3.79M | -3.22M | -1.97M | -1.1M |
| Net Interest Income | 861K | 918K | 1.02M | 954K | 930K | 1.03M | 658.41K | 95.69K | -7.96K | -2.15K | 145.4K | 130.73K |
| Interest Income | 861K | 918K | 1.02M | 954K | 930K | 1.03M | 664.72K | 104.88K | 0 | 0 | 150.74K | 139.86K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 6.31K | 9.19K | 7.96K | 2.15K | 5.34K | 9.13K |
| Other Income/Expense | 857K | 909K | 1M | 945K | 930K | 1.03M | -8.58M | 96K | 110K | 115.34K | -4.09M | -2.34M |
| Pretax Income | -15.72M | -15.54M | -15.8M | -10.85M | -10.41M | -6.27M | -3.96M | -3.58M | -3.8M | -3.23M | -1.97M | -1.11M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.72M | -15.54M | -15.8M | -10.85M | -10.41M | -6.27M | -3.96M | -3.58M | -3.8M | -3.23M | -1.97M | -1.11M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -51% | -147.96% | -299.04% | -203.41% | -173.97% | -94.29% | -100.84% | -223.14% | -170.05% | -26.55% | 32.39% | 61.33% |
| Net Income (Continuing) | -15.72M | -15.54M | -15.8M | -10.85M | -10.41M | -6.27M | -3.96M | -3.58M | -3.8M | -3.23M | -1.97M | -1.11M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.35 | -0.39 | -0.40 | -0.27 | -0.28 | -0.18 | -0.19 | -1.83 | -3.12 | -10.81 | -6.61 | -4.00 |
| EPS Growth % | -25% | -116.67% | -110.53% | 85.25% | 91.03% | 98.33% | 97.13% | 54.25% | 74.21% | 89.13% | 96.28% | 97.8% |
| EPS (Basic) | -0.35 | -0.39 | -0.40 | -0.27 | -0.28 | -0.18 | -0.19 | -1.83 | -3.12 | -10.81 | -6.61 | -4.00 |
| Diluted Shares Outstanding | 45.23M | 39.22M | 39.74M | 39.57M | 36.58M | 15.27M | 21.16M | 1.96M | 1.22M | 248.45K | 298.28K | 276.45K |
| Basic Shares Outstanding | 45.23M | 39.22M | 39.74M | 39.57M | 36.58M | 15.27M | 21.16M | 1.96M | 1.22M | 248.45K | 298.28K | 276.45K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |